Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Breast04: patritumab deruxtecan versus physician's choice treatment in HR-positive/HER2-negative advanced breast cancer
CTR20254013Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of patritumab deruxtecan in breast cancer (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Jan 2026; status: active.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254013.